Relief Therapeutics Holding SA

紹介

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disorders, and maple syrup urine disease; and PKU GOLIKE for for the dietary management of phenylketonuria. It also develops TYR GOLIKE, that has completed Phase III clinical trial to treat Tyrosinemia; and RLF-100, a synthetic form of vasoactive intestinal peptide (VIP), that is in Phase II clinical trial for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19 related ARDS and in preclinical trial to treat pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. In addition, the company also develops HCU GOLIKE, which is in Phase I clinical trial for the treatment of Homocystinuria; and RLF-TD011, a hypochlorous acid topical sprayable solution, that is in Phase I clinical trial to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. Further, it is developing RLF-OD32, which is in Phase I clinical trial for the treatment of patients with phenylketonuria; and. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland.